ESMO 2016 – Congress Highlights

ESMO Congress 2016

Kinesys Oncology: ESMO Congress, Copenhagen, 7-11 October 2016

Update on Lung Cancers, plus selected highlights in other tumours 

Lung Cancer:

RCC, Prostate, SCLC, Gastro-Oesophageal Cancers:


AstraZeneca: Selumetinib misses primary endpoint. Durvalumab: 80%, 6-month survival in Phase I / II study.

Merck’s Keytruda: Highly encouraging results in 1st and 2nd line treatment of squamous and non-squamous NSCLC.

BMS’ Opdivo: Disappointing update on 1st line treatment of NSCLC. Better results in bladder, kidney and head & neck cancer.

Roche: Positive results in 2nd / 3rd line NSCLC – PD-L1 vs non-PD-L1.

Renal Cell Carcinoma

Exelixis / Ipsen: Significant improvement in Phase II Metastatic RCC (renal cell carcinoma) trial vs sunitinib.

Prostate Cancer

OncoGenex: Disappointing results in Phase III prostate cancer for custirsen.


Takeda: Alisertib prolongs PFS in 2nd line SCLC trial.

Gastric cancer

Ganymed: IMAB362 produced significant improvements in OS, PFS and ORR in gastric / gastro-oesophageal cancer patients.

Written By sonia ziouani ammor